Cumulative Index 1986

Volume 30

ISSUES

February	THE USE OF THE CLINICAL LABORATORY IN EMERGENCY MEDICINE I
May	THE USE OF THE CLINICAL LABORATORY IN EMERGENCY MEDICINE II
August	EMERGENCY PROCEDURES
November	EMERGENCY DEPARTMENT MANAGEMENT OF CRITICAL ILLNESS

Note: Page numbers of entire articles are in **boldface** type.

Abbreviated Injury Scale, Nov., 624
Abdomen, trauma to. See *Trauma.*.
Abscesses, abdominal, Aug., 537
  Bartholian, Aug., 537
  breast, Aug., 534–535
  chest and neck, Aug., 536–537
  dental, Aug., 613
  parapharyngeal space, Aug., 612–613
  pilonidal, Aug., 534
  subepidermal, Aug., 533–534
Acid-base physiology, anion gap in, alterations in, Feb., 152–153
  arterial blood gases in, May, 237–239, 247–248
  disorders of, compensation for, Feb., 153
    mixed, Feb., 169–170
  Henderson-Hasselbalch equation for, May, 238
  normal, Feb., 146–153
    buffer systems in, Feb., 147–148
    pulmonary mechanisms in, Feb., 148–149
    renal regulation in, Feb., 149–151
Acidosis, anion gap, Feb., 160–162
  hyperchloremic, Feb., 158–160, 178
  lactic, Feb., 160–161
  metabolic, Feb., 156–158
    toxin ingestion and, Feb., 161–162
    treatment of, Feb., 162–163
  respiratory, Feb., 166–168
    causes of, May, 246
Acute myocardial infarction, coronary angioplasty during, Aug., 480–481
  clinical study of, Aug., 481–483
  diagnosis and treatment of, history of, Aug., 467–468
  interventions in, Aug., **467–486**
  intracoronary thrombolytic therapy for, Aug., 474–477
  intravenous thrombolytic therapy for, Aug., 472–474
    high-dose streptokinase, Aug., 477–481
  pathogenesis of, Aug., 470–472
  reperfusion in, pathophysiology of, Aug., 468–470

Agglutination tests, for cerebral spinal fluid, May, 292
monoclonal antibody, in pregnancy, May, 302
principles of, May, 299–300
Airways. See also *Mechanical ventilation; Ventilatory management.*
artificial, Aug., 414–415
clearing of, Aug., 413–414
esophageal obturator, Aug., 415–416
management of, Aug., **411–425**
general principles, Aug., 412
maneuvers for, Aug., 412–413
pharmacologic agents in, Aug., 421–422
surgical procedures for, Aug., 422–424
Respironics Seal Easy, Aug., 416
upper, obstruction of, C-reactive protein in, May, 383
visualization techniques for, Aug., 416–420
direct laryngoscopy, Aug., 417
fiberoptic laryngoscopy, Aug., 417–420
nasotracheal intubation, Aug., 419–420
orotracheal intubation, Aug., 418–419
tracheal intubation, Aug., 418
Alkaline phosphatase, laboratory measurement of, May, 330, 336–337
Alkalosis, metabolic, Feb., 163–166
diuretic-induced, Feb., 179–180
NaCl-resistant, Feb., 181
NaCl-responsive, Feb., 179
respiratory, Feb., 168–169
causes of, May, 246
Alveolar-arterial O_2 gradient, calculation of, in hypoxemia, Aug., 430
Amino acids, in cerebral spinal fluid, May, 291
Aminotransferases, in liver disease, May, 338
laboratory measurement of, May, 332–333, 336–337
Amylase, biochemistry of, May, 315–316
effects of drugs on, May, 322–323
in acute pancreatitis, May, 318–319
in biliary tract disease, May, 320
in cerebral trauma, May, 321
in diabetic ketoacidosis, May, 322
in gastrointestinal disease, May, 320–321
in pancreatic carcinoma, May, 320
in pancreatic pseudocysts, May, 319–320
in pancreatic trauma, May, 320
in parotid disease, May, 322
in postoperative states, May, 321
in pregnancy, May, 321, 322
in renal disease, May, 322
laboratory measurement of, May, **315–327**
clinical correlation of, May, 317
methods of, May, 316–317
Amylase:urinary creatinine clearance ratio, significance of, May, 318–319
Anal canal, infection of, Aug., 535–536
Anemia, causes of, Feb., 33
classification of, Feb., 32
red cell mean and heterogeneity in, Feb., 35
emergency department approach to, Feb., 31–36
hemolytic, Feb., 31
history and examination in, Feb., 34
megaloblastic, Feb., 29, 68
presentation of, Feb., 26–27
reticulocyte index in, Feb., 32–33
sideroblastic, Feb., 28–29
testing for, diagnostic probabilities in, Feb., 33–34
red cell distribution width in, Feb., 34, 36
Anesthetics, local, in airway management, Aug., 421
Angiography, for bladder outlet obstruction, Aug., 555–557
in trauma victim, Nov., 703, 706
abdominal, Aug., 521–522
Angioplasty, coronary, during acute myocardial infarction, Aug., 480–481
clinical study of, Aug., 481–483
Anion gap, alterations in, acid-base physiology and, Feb., 152–153
measurement of, serum chloride in, Feb., 178–179
Anisochromasia, determination of, Feb., 66–67
Anisocytosis, determination of, Feb., 64–66
Anoscopy, technique for, Aug., 509–511
Antibiotics, for soft tissue lacerations. See *Lacerations.*
Antigens, bacterial, in cerebral spinal fluid, May, 293
Antimicrobial therapy, for sepsis and septic shock. See *Sepsis.*
APACHE, in medical-surgical ICU patients, Nov., 628–629
Arrhythmias, life-threatening, Nov., **761–774**
bradyarrhythmias, Nov., 762–765
narrow-complex tachycardias, Nov., 765–767
atrial flutter or fibrillation, Nov., 767
paroxysmal supraventrical tachycardia, Nov., 766–767
sinus tachycardia, Nov., 765–766
tachycardias, Nov., 765
ventricular fibrillation, Nov., 769–771
ventricular tachycardia, Nov., 768
wide-complex PSVT, Nov., 769
wide-complex tachycardias, Nov., 767–768

Arterial blood gases, laboratory measurement of, May, **235–251**
indications for, May, 242
interpretation and clinical applications of, May, 242–248
acid-base physiology, May, 247–248
oxygenation, May, 242–245
ventilation, May, 245–247
methods of, May, 239–242
specimen acquisition for, May, 239–241
specimen analysis in, May, 241–242
physiology of, May, 235–239
acid-base, May, 237–239
oxygenation, May, 235–237
Arteriography, abdominal visceral, in trauma victim, Nov., 703
Aspirin, and prolonged bleeding time, in hemostasis, Feb., 101
Atomic Absorption Spectroscopy (AAS), in calcium determination, May, 209
Atrial fibrillation, management of, Nov., 767
Atrial flutter, management of, Nov., 767
Atropine, for bradyarrhythmias, Nov., 763–764
Azotemia, nitrogenous compounds in, May, 227–228

Bacteremia, absolute leukocyte count and, May, 389
C-reactive protein in, May, 380–381
erythrocyte sedimentation rate in, May, 385–386
Bacteriuria, determination of, May, 273–274
microbiologic studies of, May, 355–356
Beta-endorphins, in sepsis and septic shock, Nov., 820
Bicarbonate, gastrointestinal loss of, Feb., 158
in acid-base physiology, Feb., **145–173**
See also *Acid-base physiology.*
laboratory measurement of, Feb., 153–156
renal loss of, Feb., 158–159
Biliary tract, disease of, amylase in, May, 320
Bilirubin, in urinalysis, May, 270
Bites, mammalian. See *Mammalian bites.*
Bladder outlet obstruction, urologic procedures for. See *Urologic procedures.*
Bleeding, due to arterial puncture, in central venous access, Nov., 734–735
emergency department approach to, Feb., 110–111
gastrointestinal, endoscopy for, Aug., 502–505
Blister cells, on peripheral blood smear, Feb., 65
Blood, collection of, for potassium determination, Feb., 133–134
for sodium determination, Feb., 116
methods of, Feb., 19–20
loss of, significance of, Feb., 27–28
Blood cells, tests of, methods for, Feb., 20–22
Blood cultures, microbiologic studies of, May, 359–360
Blood gases, in respiratory function, Aug., 427–431
Blood smear, peripheral, Feb., **59–74**
changes on, Feb., 68–69
clinical use of, Feb., 71–72
examination of, Feb., 62–64
interpretation of, Feb., 62–71
platelet count in, Feb., 76–77
preparation of, Feb., 60–61
stains used in, Feb., 61–62
for measurement of white blood cells, Feb., 43
Blood urea nitrogen (BUN). See also *Urea.*
abnormal ranges of, causes of, May, 228
and creatinine, clinical correlation of, May, 227–231
laboratory measurement of, May, **223–233**
timing and cost of, May, 231
normal ranges of, May, 226–227
significance of, May, 228–229
Blood urea nitrogen (BUN)/creatinine ratio, changes in, May, 230–231
Bradyarrhythmias, management of, Nov., 762–765
Bradykinin, in sepsis and septic shock, Nov., 817
Bronchitis, laryngeal tracheal, Aug., 612
Buffy coat, quantitative analysis of, for measurement of white blood cells, Feb., 44–45
Burr holes, in surgery for head trauma, Nov., 870

Calcium, determination of, method of, May, 208–210
homeostasis of, disorders of, May, 210–218
hypercalcemia, May, 210–215
hypocalcemia, May, 215–218
physiology of, May, 207–208
Cancer, hypercalcemia due to, May, 211–212
Cannulation, of corpora cavernosa, for intravenous therapy, Aug., 495
Carbon dioxide, noninvasive sensors of, Nov., 802–804
conjunctival, Nov., 803–804
transcutaneous, Nov., 802–803

Carcinoma, pancreatic, amylase in, May, 320
Cardiac output, in invasive cardiorespiratory monitoring, Nov., 780
Cardiac pacing, Nov., **745–759**
emergency care of permanent pacemakers, Nov., 754–757
for bradyarrhythmias, Nov., 763
management of tachyarrhythmias, Nov., 752–754
temporary modalities for, Nov., 745–752
external automatic defibrillator-pacemaker, Nov., 752
transcutaneous pacing, Nov., 745–746
transesophageal pacing, Nov., 752
transthoracic pacing, Nov., 751–752
transvenous pacing, Nov., 746–751
Cardiorespiratory monitoring, invasive, Nov., **775–789**
cardiac output determination in, Nov., 780
central venous pressure monitoring in, Nov., 778–779
complications of, Nov., 786–787
computers in, Nov., 784–785
in shock, Nov., 775–776
mixed venous oxygen saturation in, Nov., 782–783
monitoring respiratory function in, Nov., 783–784
oxygen delivery and consumption in, Nov., 780–782
pulmonary artery monitoring in, Nov., 779–750
techniques of line placement in, Nov., 785–786
timing of institution of, Nov., 787
urine output in, Nov., 777–778
vital signs in, Nov., 776–777
noninvasive, Nov., **791–807**
arterial oxygen saturation monitoring, Nov., 801–802
CO_2 sensors, Nov., 802–804
conjunctival, Nov., 803–804
transcutaneous, Nov., 802–803
continuous monitoring of tissue *p*H, Nov., 804–805
transcutaneous and conjunctival oxygen monitoring, Aug., 435–437; Nov., 792–801
Cardiovascular function, in sepsis and septic shock. See *Sepsis*.
Casts, in urinalysis, May, 275–276
Catheters, brachial vein, for intravenous therapy, Aug., 494–495
central venous. See *Central venous access*.
CVP, fluid management and, in critically ill patient, Nov., 666–667
for bladder outlet obstruction, Aug., 543–547
placement of, in invasive cardiorespiratory monitoring, Nov., 785–786
pulmonary artery, in critically ill patient, Nov., 668–678
criteria for goals of fluid therapy in, Nov., 669, 672
development of therapeutic plan in, Nov., 674–677
fluid therapy of shock in, Nov., 673–674
hemodynamic and oxygen transport variables in, Nov., 669
monitored physiologic variables in, Nov., 669
prospective trial of outcome predictor in, Nov., 673
prospective trials of defined goals of therapy in, Nov., 677–678
tissue perfusion and oxygen transport, as criteria for therapy, Nov., 672–673
in invasive cardiorespiratory monitoring, Nov., 778–780
in shock, in infants and children, Nov., 844–845
Central venous access, in critically ill patient, Nov., **709–744**
bleeding due to arterial puncture, Nov., 734–735
catheter insertion by steel needle, Nov., 731–732
catheter removal, Nov., 741
catheter replacement, Nov., 739–740
clot formation around IV catheters, Nov., 732–734
correct catheter placement, Nov., 735
cut-downs, Nov., 727–728
fluid leakage at catheter site, Nov., 741
indications for catheterization, Nov., 709, 711
infraclavicular subclavian venipuncture, Nov., 717–718
internal jugular puncture, Nov., 718–719
internal jugular-subclavian junctional venipuncture, Nov., 716–717
intra-arterial catheters for CPR, Nov., 730
intra-atrial catheters for resuscitation, Nov., 730
intracostal and intrasternal infusions, Nov., 723
IV catheters for intra-abdominal operations, Nov., 728
percutaneous insertion of double catheters, Nov., 719–723
via femoral veins, Nov., 723

supraclavicular subclavian venipuncture, Nov., 713–716
suturing IV catheters in place, Nov., 734
teaching of, Nov., 711–712
techniques of catheter insertion, Nov., 712–713
venous blood circulation, in IV drug addicts, Nov., 730–731
x-ray control of IV catheters, Nov., 736–739
Cerebral spinal fluid, May, **281–297**
bacterial antigen in, quantitation of, May, 293
C-reactive protein in, May, 381–382
commonly used tests of, evaluation of, May, 283–289
cell count and differential, May, 286–287
clarity and composition, May, 284–285
glucose, May, 285
microscopic examination stain, May, 287, 289
opening pressure, May, 283–284
protein, May, 285–286
in tests for meningitis, May, 289–291, 291–293
agglutination tests, May, 292
amino acids, May, 291
C-reactive protein, May, 290
counterimmunoelectrophoresis, May, 291–292
enzyme-linked immunosorbent assays, May, 292–293
lactic acid, May, 289
lactic dehydrogenase, May, 289–290
limulus amebocyte lysate assay, May, 290–291
Quellung reaction, May, 290
physiology of, May, 281
technique for sampling, May, 281–283
Chemistries, performance of, laboratory equipment for, May, 401–402
Chest, blunt trauma to, branched-chain decision tree for, Nov., 688–690
Children, laboratory tests in, May, **377–397**
C-reactive protein. See *Protein, C-reactive.*
complete blood count, May, 387–390
erythrocyte sedimentation rate, May, 384–387
clinical applications of, May, 385–387
method for, May, 384
normal range of, May, 385
zeta sedimentation ratio, May, 387
shock in. See *Shock.*
Chloride, in measurement of anion gap, Feb., 178–179
laboratory measurement of, Feb., 176–177
levels of, disorders of, Feb., 177–181
high, clinical manifestations of, Feb., 181–182
physiological functions of, Feb., **175–183**
urinary, Feb., 190
Chromatography, for toxicology screening, Nov., 371–373
Chylothorax, thoracostomy for, Aug., 447
Circulatory system, physiology of, Feb., 15–18
Clinical laboratory, in emergency medicine, Feb., **1–205**; May, **207–404**
materials for, May, **397–404**
quality assurance program in, May, 402–403
STAT, design of, May, 398
equipment for, May, 399–402
chemistries, May, 401–402
hematology, May, 399–400
urinalysis, May, 400–401
staffing of, May, 398–399
tests in, decision making in, Feb., **1–14**
Clots, following surgery for head trauma, Nov., 870–871
formation of, around IV catheters, Nov., 732–734
Coagulation, evaluation of, tests for, Feb., **96**
nomenclature of, Feb., 98
studies of, Feb., **95–113**
Colon, disorders of, endoscopy for, Aug., 505–508
Colorimetry, for measurement of bicarbonate, Feb., 154, 155
for measurement of hemoglobin pigments, Feb., 21
Coma, in outcome of critically ill patient, Nov., 627
Complement fixation tests, principles of, May, 300
Complement system, in sepsis and septic shock, Nov., 816–817
Complete blood count (CBC), in children, May, 387–390
methodology of, Feb., 20–22
peripheral blood smear in, Feb., 59
Computed tomography, for bladder outlet obstruction, Aug., 558
in head trauma, Nov., 869–870
in trauma victim, Nov., 702
abdominal, Aug., 519–521
Computers, in invasive cardiorespiratory monitoring, Nov., 784–785
Contrast studies, for abdominal trauma, Aug., 523–524
Corpora cavernosa, cannulation of, for intravenous therapy, Aug., 495

Corticosteroids, for sepsis and septic shock, Nov., 835
Coulter counter, for measurement of white blood cells, Feb., 43, 44
Counterimmunoelectrophoresis, in cerebral spinal fluid, May, 291–292
CRAMS Scale, Nov., 625–626
Cranial nerves, examination of, in head trauma, Nov., 863
Creatine kinase, in myocardial disease, May, 340–341
  laboratory measurement of, May, 333–334, 337
Creatinine, abnormal values of, causes of, May, 229
  analysis of, May, 226
  and blood urea nitrogen, clinical correlation of, May, 227–231
  laboratory measurement of, May, **223–233**
  timing and cost of, May, 231
  physiology and metabolism of, May, 224–225
  significance of, May, 229–230
Cricothyrotomy, for airway management, Aug., 422–423
Critically ill patients, assessing illness severity and outcome in, Nov., **623–633**
  acute ischemic heart disease in, Nov., 627–628
  general severity of illness scores in, Nov., 628–630
    APACHE, Nov., 628–629
    multivariate models, Nov., 629–630
    TISS, Nov., 628
  limitations of severity scales and predictive models in, Nov., 630–631
  trauma scoring systems in. See *Trauma scoring systems.*
  univariate predictors of ICU outcome in, Nov., 626–627
  central venous access in. See *Central venous access.*
  resuscitation of. See *Resuscitation.*
  ventilatory management of. See *Ventilatory management.*
Croup, clinical presentation of, Aug., 611–612
CT. See *Computed tomography.*
Cvostek sign, in hypocalcemia, May, 217–218
Cystography, for bladder outlet obstruction, Aug., 551, 554–555
Cysts, epidermal inclusion, clinical presentation of, Aug., 533
Cytochemistry, continuous flow, for measurement of white blood cells, Feb., 44

Decompression, nasogastric, in trauma victim, Nov., 699–700
Dehydration, and dyshydration, in critically ill patient, Nov., 664
Detorsion, spermatic cord, procedure for, Aug., 547
Differential heterophile antibody test, for infectious mononucleosis, May, 311–313
Disseminated intravascular coagulation (DIC), determination of, Feb., 109–110
Diuretics, and metabolic alkalosis, Feb., 179–180
Dobutamine, for sepsis and septic shock, Nov., 833
Dohle inclusion bodies, on peripheral blood smear, Feb., 69–70
Dopamine, for sepsis and septic shock, Nov., 833
Doppler ultrasound, of testes, Aug., 557–558
Drug addicts, venous blood circulation in extremities of, Nov., 730–731
Drugs, hyperamylasemia due to, May, 322–323
  quantitative tests for, May, 369
  therapeutic levels of, and toxicology screening. See *Toxicology screening.*

Ears, foreign bodies in, Aug., 613
Effusions, pleural, thoracostomy for, Aug., 446–447
Electrolytes, urinary. See *Urinary electrolytes.*
Empyema, thoracostomy for, Aug., 447
Endoscopy, gastrointestinal, Aug., **501–512**
  for bleeding, Aug., 502–505
    massive, of lower tract, Aug., 504–505
    of upper tract, Aug., 502–504
  for colon disorders, Aug., 505–508
    pseudo-obstruction, Aug., 506–508
    sigmoid volvulus, Aug., 506
  for foreign bodies, Aug., 508–509
Endotoxin core glycolipid, antibody to, for sepsis and septic shock, Nov., 835–836
Enzyme-linked immunosorbent assays, for cerebral spinal fluid, May, 292–293
Enzymes, serum. See *Serum enzymes.*
Eosinophils, on peripheral blood smear, Feb., 70
Epiglottitis, acute, Aug., 611
Epistaxis, in nasal fractures, Aug., 607
Epithelial cells, in urinalysis, May, 272
Erythrocyte sedimentation rate (ESR), clinical applications of, May, 385–387
  determination of, Feb., **87–93**
  interpretation of, Feb., 90–92
  methodology of, Feb., 88–90; May, 384
  normal range of, May, 385
  physiology of sedimentation in, Feb., 87–88
Erythrocytes, abnormal parameters of, clinical interpretation of, Feb., 25–31
  assessment of, Feb., 15–18

characteristics of, Feb., 16–17
circulating, increase in, Feb., 36–38
damage to, after leaving bone marrow, Feb., 67
decreased production of, Feb., 28–30
in urinalysis, May, 271, 272
increased destruction of, Feb., 30–31
indexes of, Feb., 23
metabolic pathways of, Feb., 17
morphology of, effect of disease process on, Feb., 64
variants of, Feb., 63
normal degradation of, Feb., 18
shape of, variation in, Feb., 64–66
size of, variation in, Feb., 64–66
Erythropoiesis, assessment of, Feb., 16
compensatory, effects of, Feb., 67–68
Ethanol intoxication, osmolality in determination of, May, 258–260
Extubation, in critically ill patient, Nov., 653

Factor XIII, deficiency of, Feb., 110
Feces, microbiologic studies of, May, 361
Femoral veins, catheters inserted via, Nov., 723
Fibrillation, atrial, management of, Nov., 767
ventricular, for ventricular tachycardia, Nov., 770
Fistula-in-ano, clinical presentation of, Aug., 536
Fluids, management of, in critically ill patient. See *Resuscitation.*
Fluorescent antibody tests, principles of, May, 300
Flutter, atrial, management of, Nov., 767
Folliculitis, clinical presentation of, Aug., 532–533
Foot, puncture wounds of, Aug., 581–582
Foreign bodies, in ear, Aug., 613
in gastrointestinal tract, endoscopy for, Aug., 508–509
in larynx, Aug., 610–611
Fractures, mandibular, Aug., 608
nasal, Aug., 606–607
orbital, Aug., 609

Gas exchange, hemoglobin and, Feb., 17–18
Gastrointestinal tract, bleeding in, endoscopy for, Aug., 502–505
contrast studies of, Aug., 523
disease of, amylase in, May, 320–321
foreign bodies in, endoscopy for, Aug., 508–509
Genital tract, female, microbiologic studies of, May, 357–359
male, microbiologic studies of, May, 356–357
Glasgow Coma Scale, Nov., 624, 626, 629, 864, 871, 872
Glucose, abnormal levels of, management of, Feb., 198–202
estimation of, reagent strip systems for, Feb., 194–196
in urinalysis, May, 268–269
laboratory measurement of, Feb., 196–198
physiology of, Feb., 193–194
regulation of, Feb., 193–205
significance of, in cerebral spinal fluid, May, 285

Hageman factor, in sepsis and septic shock, Nov., 816
Hands, minor lacerations of, antimicrobial treatment for, clinical trials of, Aug., 567–570
HCG, in pregnancy, May, 300–301
Head, trauma to. See *Trauma.*
amylase in, May, 321
Heinz bodies, on peripheral blood smear, Feb., 68–69
Hematocrit, in polycythemia, Feb., 38
measurement of, Feb., 21–22
Hematology, laboratory equipment for, May, 399–400
normal values in, Feb., 24–25
Hematuria, determination of, May, 272–273
Hemoglobin, alterations in, Feb., 66–67
and gas exchange, Feb., 17–18
catabolism of, Feb., 18
concentration of, measurement of, Feb., 20–21
automated methods for, Feb., 24
Hemoglobin/hematocrit, and other erythrocyte parameters, Feb., 15–40
Hemolysis, metabolic changes following, Feb., 30–31
Hemostasis, bleeding time in, Feb., 99–100
abnormal, causes of, Feb., 100–102
aspirin and, Feb., 101
prolongation of, drug-induced, Feb., 101
coagulation phase of, Feb., 97–99
common pathway defects in, Feb., 109
disseminated intravascular coagulation in, Feb., 109–110
extrinsic pathway defects in, Feb., 107–109
factor XIII deficiency in, Feb., 110
fibrinolytic phase of, Feb., 99
historic perspective of, Feb., 95–96
intrinsic pathway defects in, Feb., 106–107

Hemostasis (*Continued*)
laboratory tests for, Feb., 99–104
artifacts in, Feb., 104–106
blood collection for, Feb., 104–106
partial thromboplastin time in, Feb., 103–104
abnormal values for, Feb., 106–110
physiology of, Feb., 96–99
platelet phase of, Feb., 97
prothrombin time in, Feb., 102–103, 104
abnormal values of, Feb., 106–110
vascular phase of, Feb., 96–97
Hemothorax, thoracostomy for, Aug., 442–443
Henderson-Hasselbalch equation, for acid-base physiology, May, 238
Hepatic dysfunction, in outcome of critically ill patient, Nov., 627
Hepatitis, following needlestick punctures, type B, Aug., 585–587
type non-A/non-B, Aug., 587–589
immunoglobulins for, Aug., 587–589
post-exposure prophylaxis for, Aug., 589–591
viral. See *Viral hepatitis*.
Hidradenitis, clinical presentation of, Aug., 534
Histamine, in sepsis and septic shock, Nov., 817
Hoarseness, clinical presentation of, Aug., 611
Howell-Jolly bodies, on peripheral blood smear, Feb., 69
Humidification, and mechanical ventilation, Nov., 646–647
Hypercalcemia, causes of, May, 210–212
laboratory tests for, May, 214
signs and symptoms of, May, 213
treatment of, May, 214–215
Hyperchloremia, determination of, Feb., 177–178
Hyperglycemia, causes of, Feb., 201
determination of, Feb., 200–202
Hyperkalemia, causes of, Feb., 138
clinical symptoms of, Feb., 139
determination of, Feb., 137–138
electrocardiographic effects of, Feb., 139
Hypernatremia, clinical features of, Feb., 126–127
determination of, Feb., 124–128
differential diagnosis of, Feb., 125
treatment of, Feb., 127–128
with high total body sodium, Feb., 126
with low total body sodium, Feb., 125
with normal total body sodium, Feb., 126
Hyperparathyroidism, hypercalcemia due to, May, 210–211
Hypervitaminosis, hypercalcemia due to, May, 212
Hypocalcemia, causes of, May, 215–216
signs and symptoms of, May, 217–218
treatment of, May, 217, 218
Hypochloremia, determination of, Feb., 179–181
Hypochromasia, determination of, Feb., 66
Hypoglycemia, causes of, Feb., 199
determination of, Feb., 198–200
Hypokalemia, causes of, Feb., 136
clinical symptoms of, Feb., 139
determination of, Feb., 135–137
electrocardiographic effects of, Feb., 139
Hyponatremia, causes of, Feb., 118
clinical features of, Feb., 123
determination of, Feb., 117–124, 189
differential diagnosis of, Feb., 119
diminished chloride intake and, Feb., 180
treatment of, Feb., 123–124
with high total body sodium, Feb., 122–123
with low total body sodium, Feb., 119–120
with normal total body sodium, Feb., 120–122
Hypoventilation, hypoxemia due to, Aug., 428
Hypovitaminosis, hypocalcemia due to, May, 216–217
Hypoxemia, causes of, Aug., 428–430

Immunoassays, for toxicology screening, May, 373–374
in pregnancy, May, 301–302, 303
Immunoglobulins, for type B hepatitis, post-exposure prophylaxis for, Aug., 589–591
for type non-A/non-B hepatitis, following needlestick punctures, Aug., 587–589
Incision and drainage, assessment of soft tissue infection for, Aug., 527–528
procedures for, Aug., **527–542**. See also *Infections*.
surgical techniques for, Aug., 537–539
wound management following, Aug., 539–541
Infarction, acute myocardial. See *Acute myocardial infarction*.
Infections, due to abscesses in deep structures, Aug., 535–537
abdomen, Aug., 537
anal canal, Aug., 535–536
bacterial lymphadenitis, Aug., 536–537
Bartholin's gland, Aug., 537
chest and neck, Aug., 536–537
fistula-in-ano, Aug., 536
inflammatory bowel disease, Aug., 536
due to mammalian bites, Aug., 595–596

incision and drainage of, surgical techniques for, Aug., 537–539
wound management following, Aug., 539–541
life-threatening, C-reactive protein in, May, 381
of skin and appendages, microbiologic studies of, May, 359
of skin and appendages, Aug., 532–535
breast abscess, Aug., 534–535
epidermal inclusion cysts, Aug., 533
folliculitis, Aug., 532–533
hidradenitis, Aug., 534
paronychia, Aug., 533
pilonidal abscess, Aug., 534
subepidermal abscess, Aug., 533–534
of soft tissue, assessment of, Aug., 527–528. See also *Lacerations*.
anatomic and pathophysiologic considerations in, Aug., 531–532
ancillary diagnostic maneuvers in, Aug., 530
history in, Aug., 528
physical examination in, Aug., 528–530
Inflammatory bowel disease, clinical presentation of, Aug., 536
Infusions, intracostal and intrasternal, Nov., 723
intraosseous. See *Intravenous therapy*.
Intravenous pyelography, for bladder outlet obstruction, Aug., 550
of urinary tract, Aug., 524
Intravenous therapy, alternative access sites for, Aug., 491–499
brachial vein catheterization, Aug., 494–495
corpora cavernosa cannulation, Aug., 495
intravenous pressure-flow relationship, Aug., 495–496, 499
saphenous vein cutdown, Aug., 493–494
Seldinger technique, Aug., 491–493
intraosseous infusion in, Aug., 487–491
anatomy in, Aug., 487
complications of, Aug., 489–490
contraindications to, Aug., 489
history of, Aug., 488–489
indications for, Aug., 489
pharmacokinetics of, Aug., 490–491
technique for, Aug., 489
recent advances in, Aug., **487–500**
Intubation. See also *Airways*.
for airway visualization, Aug., 418–419
pharmacologic agents in, Aug., 421–422
indications for, in critically ill patient, Nov., 636
nasotracheal, Aug., 419–420
in head trauma, Nov., 869
Iron, deficiency of, Feb., 29–30, 67
Ischemic heart disease, acute, in outcome of critically ill patient, Nov., 627–628
Isoproterenol, for bradyarrhythmias, Nov., 764

Jaundice, cholestatic, serum enzymes in, May, 338–339

Ketoacidosis, determination of, Feb., 160
diabetic, amylase in, May, 322
Ketones, in urinalysis, May, 269–270
Kidneys, disease of, amylase in, May, 322
effect of hypercalcemia on, May, 213
effect of hypocalcemia on, May, 217
function of, failure of, Feb., 160
regulation of, acid-base physiology in, Feb., 149–151
Killip Classification, of acute ischemic heart disease, Nov., 627

Laboratory, clinical, in emergency medicine, Feb., **1–205**; May, **207–404**
Laboratory tests, clinical usefulness of, Feb., 9–13
cost-benefit ratio in, Feb., 9–11
decision analysis in, Feb., 11–13
decision making in, Feb., **1–14**
evaluation of, Feb., 1–2
in children. See *Children*.
reasons for ordering, Feb., 2–3
results of, evaluation of, Feb., 3–9
predictive value matrix in, Feb., 4, 6–9
Lacerations, soft tissue, antimicrobial treatment of, Aug., **561–580**
clinical study of, Aug., 563–565
clinical trials of, Aug., 565–572
for animal bites, Aug., 570–572
for minor lacerations, Aug., 565–567
of hand, Aug., 567–570
indications for, Aug., 577–579
preventive, Aug., 562–563
determinants of infection in, Aug., 572–577
anatomic site, Aug., 572–574
clinical appearance, Aug., 574–575
subcutaneous sutural closure, Aug., 576–577
surgical experience, Aug., 577
time since injury, Aug., 575–576
Lactate dehydrogenase, in myocardial disease, May, 340–341
laboratory measurement of, May, 334–335, 337

Lactic acid, in cerebral spinal fluid, May, 289
Lactic dehydrogenase, in cerebral spinal fluid, May, 289–290
Laparotomy, exploratory, for abdominal trauma, Aug., 522–523
Laryngoscopy, for airway visualization, direct, Aug., 417
fiberoptic, Aug., 417–420
Larynx, foreign body inspiration in, Aug., 610–611
trauma to, Aug., 609–614
Lavage, peritoneal. See *Peritoneal lavage.*
Leukocytes, classification of, Feb., 69–70
in urinalysis, May, 271, 273–274
increase in, in cerebral spinal fluid, May, 288
Leukocytosis, differential diagnosis of, Feb., 48–51
lymphocytic, Feb., 51
neutrophilic, Feb., 48–49, 51
Leukopenia, determination of, Feb., 51
Levarterenol, for sepsis and septic shock, Nov., 833
Lidocaine, for ventricular tachycardia, Nov., 768
Limulus amebocyte lysate assay, in cerebral spinal fluid, May, 290–291
Lipopolysaccharides, in sepsis and septic shock, Nov., 815–816
Liver, disease of, enzymatic evaluation of, May, 337–339
Lumbar puncture, for cerebral spinal fluid sampling, May, 281–283
Lymphadenitis, bacterial, clinical presentation of, Aug., 536–537
Lymphocytes, on peripheral blood smear, Feb., 70

Macroamylase, significance of, May, 317
Mammalian bites, antimicrobial treatment for, clinical trials of, Aug., 570–572
biology of infection from, Aug., 595–596
management of, Aug., **595–604**
penicillin G in, Aug., 598–599
rabies prophylaxis in, Aug., 599–603
adverse reactions to, Aug., 602
criteria for, Aug., 599–601
vaccine for, Aug., 601–603
tissue examination in, Aug., 597–598
mechanism of injury from, Aug., 596–597
Mandible, fracture of, Aug., 608
Maxillofacial trauma, management of. See *Otolaryngology, emergencies in.*
Mechanical ventilation, in critically ill patient. See also *Airways; Ventilatory management.*
adjuncts to, Nov., 644–647
humidification, Nov., 646–647
oxygen therapy, Nov., 644–645
positive end-expiratory pressure, Nov., 645–646
sighs, Nov., 647
indications for, Nov., 636–638
Meningitis, neonatal, C-reactive protein in, May, 381
tests for, cerebral spinal fluid in. See *Cerebral spinal fluid.*
Meningococcemia, erythrocyte sedimentation rate in, May, 386
Mental status, examination of, in head trauma, Nov., 862–863
Microbiologic studies, May, **345–365**
culture media for, May, 351
inoculation and incubation of, May, 351, 353
in female genital tract, May, 357–359
in lower respiratory tract, May, 360–361
in male genital tract, May, 356–357
in pharyngitis, May, 354–355
in skin infections and wounds, May, 359
in urethritis, May, 356–357
in urinary tract infections, May, 355–356
of blood cultures, May, 359–360
of stool specimens, May, 361
slide preparation for, May, 347–350
specimen collection for, May, 345–347
anaerobic, May, 350–351
Military antishock trousers (MAST), in head trauma, Nov., 861
Monocytes, on peripheral blood smear, Feb., 70
Mononucleosis, infectious, serologic tests for, May, 311–313
Monospot test, for infectious mononucleosis, May, 311–313
Myocardial disease, enzymatic evaluation of, May, 339–341

Naloxone, for sepsis and septic shock, Nov., 835
Nasogastric decompression, in trauma victim, Nov., 699–700
Neck, examination of, in head trauma, Nov., 862
Needlestick punctures, hepatitis following, type B, Aug., 585–587
type non-A/non-B, Aug., 587–589
immunoglobulins for, Aug., 587–589
management of, Aug., **581–593**
Nerve block, regional, in puncture wounds, Aug., 582–584
Nerves, cranial, examination of, in head trauma, Nov., 863

Neurologic examination, in head trauma, Nov., 862–864
Neutropenia, drugs causing, Feb., 50
Neutrophils, on peripheral blood smear, Feb., 69–70
Nitrites, in urinalysis, May, 271
Nitroglycerin, for sepsis and septic shock, Nov., 833
Nitroprusside, for sepsis and septic shock, Nov., 833
Nose, fracture of, Aug., 606–607
Nuclear imaging, of testes, Aug., 558
Nuclear scintigraphic studies, in trauma victim, Nov., 702–703

Orbit, fracture of, Aug., 609
Organogenicity, erythrocyte sedimentation rate in, May, 386–387
Osmolality, laboratory measurement of, May, **253–261**
  analytical methods of, May, 254–256
  clinical applications of, May, 257–260
  physiology of, May, 253–254
  serum, calculation of, May, 256–257
Osteomyelitis, following puncture wounds, Aug., 584–585
Otolaryngology, emergencies in, Aug., **605–614**
  dental infection and abscess, Aug., 613
  laryngeal trauma, Aug., 609–614
    acute epiglottitis, Aug., 611
    bronchitis, Aug., 612
    croup, Aug., 611–612
    foreign body in ear, Aug., 613
    foreign body in larynx, Aug., 610–611
    hoarseness, Aug., 611
    parapharyngeal space abscess, Aug., 612–613
    perforation of tympanic membrane, Aug., 613–614
    pharyngitis, Aug., 612
    tonsillitis, Aug., 612
  maxillofacial trauma, Aug., 605–609
    mandibular fractures, Aug., 608
    nasal fractures, Aug., 606–607
      epistaxis in, Aug., 607
    orbital fractures, Aug., 609
Oximeters, ear and fingertip, in noninvasive arterial oxygen saturation monitoring, Nov., 801–802
Oxygen, arterial saturation of, noninvasive monitoring of, Nov., 801–802
  decreased inspiration of, hypoxemia due to, Aug., 430
  delivery and consumption of, in invasive cardiorespiratory monitoring, Nov., 780–782
  mixed venous saturation of, 782–783
  transcutaneous and transconjunctival monitoring of, in respiratory function, Aug., 435–437; Nov., 792–801
Oxygen therapy, and mechanical ventilation, Nov., 644–645
Oxygenation, arterial blood gases in, May, 235–237, 242–245

Pacing, cardiac. See *Cardiac pacing.*
Pancreas, cancer of, amylase in, May, 320
  trauma to, amylase in, May, 320
Pancuronium bromide, in airway management, Aug., 422
Papilledema, and lumbar puncture, May, 282–283
Pappenheimer bodies, on peripheral blood smear, Feb., 69
Paronychia, clinical presentation of, Aug., 533
Parotitis, amylase in, May, 322
Partial thromboplastin time, in hemostasis, Feb., 103–104
  abnormal values for, Feb., 106–110
  prolonged, differential diagnosis of, Feb., 106
Peak flow meters, in respiratory function, Aug., 434–435
Pelvic inflammatory disease, microbiologic studies of, May, 358–359
Peritoneal lavage, for abdominal trauma, Aug., 515–519; Nov., 701–702
  interpretation of, Aug., 519
  techniques for, closed, Aug., 516–518
    open, Aug., 518–519
    semiopen, Aug., 518
Pharyngitis, clinical presentation of, Aug., 612
  microbiologic studies of, May, 354–355
Platelet count, Feb., **75–85**
  measurement of, methods of, Feb., 76–78
  quantitative, interpretation of, Feb., 78–83
Platelets, in clot formation, Feb., 75–76
  on peripheral blood smear, Feb., 70–71
  physiology of, Feb., 75–76
Pleural effusions, thoracostomy for, Aug., 446–447
Pneumothoraces, thoracostomy for. See *Thoracostomy.*
Poikilocytosis, determination of, Feb., 64–66
Polycythemia, determination of, Feb., 36–38
Positive end-expiratory pressure (PEEP), and mechanical ventilation, Nov., 645–646

Positive-pressure ventilation (PPV), physiologic implications of, Nov., 640–641
Postconcussion syndrome, following surgery for head trauma, Nov., 872–873
Potassium, abnormal values of, treatment of, Feb., 140–141
biologic role of, Feb., **131–144**
disorders of, Feb., 135–139
in intracellular fluid, Feb., 132–133
levels of, costs of determining, Feb., 141
testing for, Feb., 133–135
physiology and metabolism of, Feb., 131–133
urinary, Feb., 190–191
Precipitin tests, principles of, May, 300
Pregnancy, amylase in, May, 321, 322
serologic tests in. See *Serologic tests.*
Procainamide, for wide-complex PSVT, Nov., 769
Prostaglandins, in sepsis and septic shock, Nov., 817, 820
Protein, C-reactive, in cerebral spinal fluid, May, 285–286, 290
laboratory measurement of, May, 377–384
clinical applications of, May, 379–381
development of test for, May, 378–379
elevated levels in, May, 379
in cerebral nervous system syndromes, May, 381–382
in immunocompromised host, May, 382–383
in upper airway obstruction, May, 383
in urinary tract disease, May, 383–384
normal range of, May, 379
physiology of, May, 378
in urinalysis, May, 269
response of, to stress, Nov., 664–665
Prothrombin time, in hemostasis, Feb., 102–103, 104
abnormal values for, Feb., 106–110
prolonged, differential diagnosis of, Feb., 108
Pseudo-obstruction, of colon, endoscopy for, Aug., 506–508
Pseudocysts, pancreatic, amylase in, May, 319–320
Pseudohypoparathyroidism, hypocalcemia due to, May, 215
Pulmonary capillary wedge pressure, in invasive cardiorespiratory monitoring, Nov., 779–780
Puncture wounds, management of, Aug., **581–593**
of foot, Aug., 581–582
osteomyelitis following, Aug., 584–585
regional nerve block in, Aug., 582–584
Pyelogram, intravenous, in bladder outlet obstruction, Aug., 550
of urinary tract, Aug., 554
Pyuria, determination of, May, 273–274

Queckenstedt test, for cerebral spinal fluid sampling, May, 284
Quellung reaction, in cerebral spinal fluid, May, 290

Rabies, due to mammalian bites. See *Mammalian bites.*
Radioimmunoassays, in pregnancy, May, 303
Radiology, noninvasive, in trauma victim, Nov., 702–703
Radionuclide scintigraphy, for abdominal trauma, Aug., 524–525
Radioreceptor assays, in pregnancy, May, 302–303
Reagent strips, for glucose estimation, Feb., 194–196
Reflexes, examination of, in head trauma, Nov., 863–864
Renin-angiotensin system, in sepsis and septic shock, Nov., 820
Reperfusion, in acute myocardial infarction, pathophysiology of, Aug., 468–470
streptokinase in, Aug., 474
Respiratory failure, acute vs. chronic, in critically ill patient, Nov., 635–636
in outcome of critically ill patient, Nov., 627
Respiratory function, in invasive cardiorespiratory monitoring, Nov., 783–784
procedures for, Aug., **427–440**
blood gases, Aug., 427–431
hypoxemia determination by, Aug., 428–431
peak flow meters, Aug., 434–435
spirometry, Aug., 431–433
transcutaneous and transconjunctival monitoring, Aug., 435–437; Nov., 792–801
Respiratory tract, lower, microbiologic studies of, May, 360–361
Resuscitation, intra-arterial catheters in, Nov., 730
of critically ill patient, blunt trauma to chest and abdomen in, branched-chain decision tree for, Nov., 688–690
branched-chain decision trees to improve outcome, Nov., **655–694**
choice of fluid in, Nov., 678–688
physiologic effects of crystalloids vs. colloids in, in prospective clinical trials, Nov., 678–681, 683, 687

recommendations for fluid therapy, Nov., 687–688
fluid abnormalities in, Nov., 664–666
clinical criteria for fluid therapy, Nov., 666
dehydration and dyshydration, Nov., 664
protein response to stress, Nov., 664–665
fluid management in, Nov., 656–664
and CVP catheters, Nov., 666–667
efficacy of algorithm in, Nov., 662–663
evaluation of CVP decision nodes in, Nov., 663–664
multiple deviations from algorithm in, Nov., 661–662
specific decision nodes of algorithm in, Nov., 663
pulmonary artery catheters in. See *Catheters*.
Reticulocytes, on peripheral blood smear, Feb., 68

Saphenous vein cutdown, for intravenous therapy, Aug., 493–494
Scalp, examination of, in head trauma, Nov., 862
Scintigraphy, radionuclide, for abdominal trauma, Aug , 524–525
Seizures, following surgery for head trauma, Nov., 872
Seldinger technique, for intravenous therapy, Aug., 491–493
Sepsis, and septic shock, Nov., **809–839**
clinical presentation of, Nov., 811–814
epidemiology, Nov., 809–811
in infants and children, Nov., 853–855
pathophysiology of, Nov., 814–827
bradykinin, Nov., 817
cardiovascular function, Nov., 821–825
afterload, Nov., 822
heart rate, Nov., 823
myocardial function, Nov., 823–825
preload, Nov., 821–822
pulmonary vascular function, Nov., 823
systemic vascular function, Nov., 822–823
host mediators and reflex responses, Nov., 816–817
initial trigger, Nov., 815–816
metabolic derangements and organ failure, Nov., 825–826
prostaglandins, Nov., 817, 820
respiratory injury, Nov., 826
structural and functional changes, Nov., 826–827
treatment of, Nov., 827–836
antibody to endotoxin core glycolipid, Nov., 835
antimicrobial therapy, Nov., 828–829
cardiovascular therapeutics, Nov., 829, 832
corticosteroids, Nov., 835
dobutamine, Nov., 833
dopamine, Nov., 833
levarterenol, Nov., 833
naloxone, Nov., 835
nitroglycerin, Nov., 833
nitroprusside, Nov., 833
target organ support, Nov., 833
vasoactive drug therapy, Nov., 832–833
volume resuscitation, Nov., 832
in invasive cardiorespiratory monitoring, Nov., 786
neonatal, C-reactive protein in, May, 381
erythrocyte sedimentation rate in, May, 386
Serologic tests, May, **299–314**
for infectious mononucleosis, May, 311–313
in pregnancy, May, 300–305
accuracy of, May, 303–304
cost analysis of, May, 305
enzyme immunoassays, May, 303
HCG, May, 300–301
immunoassays, May, 301–302
monoclonal antibody agglutination, May, 302
radioimmunoassays, May, 303
radioreceptorassays, May, 302–303
principles of, May, 299–300
Serum enzymes, laboratory measurement of, May, **329–342**
alkaline phosphatase, May, 330
aminotransferases, May, 332–333
creatine kinase, May, 333–334
in liver disease, May, 337–339
in myocardial disease, May, 339–341
lactate dehydrogenase, May, 334–335
methods of, May, 336–337
timing and cost of, May, 341
Shock, in infants and children, Nov., **841–857**
developmental physiologic considerations, Nov., 843–855
cardiogenic shock, Nov., 847–848, 852–853
hypovolemic shock, Nov., 845–847
monitoring, Nov., 844–845
septic shock, Nov., 853–855
invasive cardiorespiratory monitoring in, Nov., 775–776
septic. See *Sepsis*.
Shunts, right-to-left, hypoxemia due to, Aug., 428–429
Sickle cells, on peripheral blood smear, Feb., 65, 66

Sighs, and mechanical ventilation, Nov., 647
Sigmoid volvulus, endoscopy for, Aug., 506
Sodium, in extracellular fluid, physiology of, Feb., 115–116
laboratory determination of, Feb., 116–117
metabolism of, Feb., **115–130**. See also *Hypernatremia; Hyponatremia.*
urinary, Feb., 188–190
Somogyi units, of amylase activity, May, 317
Spectroscopy, ultraviolet, for toxicology screening, May, 371
Spherocytes, on peripheral blood smear, Feb., 65–66
Spirometry, in respiratory function, Aug., 431–433
Spot tests, for toxicology screening, May, 371
Sputum, microbiologic studies of, May, 360–361
Stains, in microscopic examination, of cerebral spinal fluid, May, 287, 289
Streptokinase, for acute myocardial infarction, high-dose intravenous, Aug., 477–481
intracoronary, Aug., 474–477
intravenous, Aug., 472–474
Stress, protein response to, Nov., 664–665
Succinylcholine, in airway management, Aug., 422
Surgery, amylasemia following, May, 321
for head trauma, Nov., 870–871
Sympathetic nervous system, in sepsis and septic shock, Nov., 820
Syndrome of inappropriate antidiuretic hormone (SIADH), determination of , Feb., 120–122, 190
Systemic arterial blood pressure (SAP), in invasive cardiorespiratory monitoring, Nov., 776–777

Tachyarrhythmias, pacing management of, Nov., 752–754
Tachycardias. See *Arrhythmias.*
Testes, Doppler ultrasound of, Aug., 557–558
nuclear imaging of, Aug., 558
Thalassemia, determination of, Feb., 28
variations of, Feb., 66
Thoracostomy, Aug., **441–457**
contraindications to, Aug., 447
for non-traumatic conditions, chylothorax, Aug., 447
empyema, Aug., 447
hemopneumothorax, Aug., 445–447
pleural effusions, Aug., 446–447
spontaneous pneumothorax, Aug., 445–446
for traumatic conditions, Aug., 442–445
open pneumothorax, Aug., 444–445
pneumothorax, hemothorax, and hemopneumothorax, Aug., 442–443
tension pneumothorax, Aug., 443–444
procedure for, Aug., 447–454
aftercare for, Aug., 452, 454
complications of, Aug., 455–456
equipment and supplies for, Aug., 448
patient preparation for, Aug., 449
site for, Aug., 449
tube, in trauma victim, Nov., 700
Thoracotomy, Aug., **459–464**
complications of, Aug., 464
indications and contraindications for, Aug., 460–462
technique for, Aug., 462–464
Thrombocytopenia, causes of, Feb., 79
determination of, Feb., 78–82
Thrombocytosis, determination of, Feb., 82–83
Thrombolytic therapy, for acute myocardial infarction, intracoronary, Aug., 474–477
intravenous, Aug., 472–474
Thrombus, occlusive coronary, acute myocardial infarction due to, Aug., 470–472
TISS, in medical-surgical ICU patients, Nov., 628
Tissue *p*H, continuous monitoring of, Nov., 804–805
Tobey Ayer test, for cerebral spinal fluid sampling, May, 284
Tonsillitis, clinical presentation of, Aug., 612
Toxicology screening, analytic methods for, May, 371–374
chromatography, May, 371–373
immunoassays, May, 373–374
spot tests, May, 371
ultraviolet spectroscopy, May, 371
and therapeutic drug levels, May, **367–376**
specimen acquisition for, May, 370
STAT requisition form for, May, 367–368
Toxins, ingestion of, and metabolic acidosis, Feb., 161–162
Transcutaneous and transconjunctival monitoring, in respiratory function, Aug., 435–437; Nov., 792–801
Translaryngeal jet ventilation (TLJV), in airway management, Aug., 422–423
Trauma. See also *Trauma victim.*
blunt, to chest and abdomen, branched-chain decision tree for, Nov., 688–690
to abdomen, angiography for, Aug., 521–522
computed tomography for, Aug., 519–521
contrast studies for, Aug., 523–524
diagnostic procedures for, Aug., **513–526**
purposes of, Aug., 515

exploratory laparotomy for, Aug., 522–523
history and physical examination for, Aug., 513–515
peritoneal lavage for. See *Peritoneal lavage.*
radionuclide scintigraphy and ultrasonography for, Aug., 524–525
to head, Nov., **859–874**
amylase in, May, 321
basic management of, Nov., 865–869
Group I patients, Nov., 865–866
Group II patients, Nov., 866
Group III patients, Nov., 866–869
Group IV patients, Nov., 869
complications following, Nov., 872–873
epidemiology, Nov., 859–860
further evaluation and treatment of, Nov., 869–870
neurologic evaluation of, Nov., 862–864
scales for grading injury, Nov., 864
outcome of, Nov., 871–872
surgical treatment of, Nov., 870–871
treatment of, Nov., 860–861
to larynx, Aug., 609–614
Trauma Score, Nov., 624–625
Trauma scoring systems, Nov., Nov., 624–626
Abbreviated Injury Scale, Nov., 624
CRAMS Scale, Nov., 625–626
Glasgow Coma Scale, Nov., 624, 626, 629, 864, 871, 872
Trauma Score, Nov., 624–625
Trauma victim. See also *Trauma.*
surgical preparation of, Nov., **695–708**
communication with family members, Nov., 700
establishment of treatment priorities, Nov., 697
laboratory evaluation, Nov., 698
medication, Nov., 700
need for specialty consultation, Nov., 700–701
physical examination, Nov., 697–698
procedures, Nov., 698–700
nasogastric decompression, Nov., 699–700
tube thoracostomy, Nov., 700
vascular access, Nov., 698–699
venous cut-down, Nov., 698–699
selection of diagnostic procedures, Nov., 701–706
angiography, Nov., 703, 706
noninvasive radiology, Nov., 702–703
peritoneal lavage, Nov., 701–702
Trousseau sign, in hypocalcemia, May, 217–218
Tube thoracostomy, in trauma victim, Nov., 700
Tympanic membrane, perforation of, Aug., 613–614
Ultrasonography, for abdominal trauma, Aug., 524–525
for bladder outlet obstruction, Aug., 555
of testes, Aug., 557–558
Urea. See also *Blood urea nitrogen.*
analysis of, May, 225–226
physiology and metabolism of, May, 223–224
Urethritis, microbiologic studies of, May, 357–359
Urethrography, for bladder outlet obstruction, Aug., 551
Urinalysis, in bladder outlet obstruction, Aug., 548
laboratory performance of, May, **263–279**
equipment for, May, 400–401
specimen acquisition for, May, 263–265
specimen analysis in, May, 265–276
bacteria in, May, 274
bilirubin in, May, 270
casts in, May, 275–276
color, appearance, and odor in, May, 266, 267
epithelial cells in, May, 272
glucose in, May, 268–269
ketones in, May, 269–270
methods of, May, 265–266
nitrites in, May, 271
pH in, May, 268
protein in, May, 269
red blood cells in, May, 271, 272
specific gravity in, May, 266, 268
urobilinogen in, May, 270–271
white blood cells in, May, 271, 273–274
Urinary electrolytes, Feb., **185–192**
clinical use of, Feb., 188–191
laboratory measurement of, Feb., 187
physiology of, Feb., 185–187
Urinary tract, contrast studies of, Aug., 523–524
disease of, C-reactive protein in, May, 383–384
infections of, microbiologic studies of, May, 355–356
intravenous pyelogram of, Aug., 554
Urine, laboratory assessment of. See *Urinalysis.*
output of, in invasive cardiorespiratory monitoring, Nov., 777–778
Urobilinogen, in urinalysis, May, 270–271
Urography, excretory, for bladder outlet obstruction, Aug., 549–550
Urologic procedures, for bladder outlet obstruction, Aug., **543–560**
diagnostic procedures, Aug., 548–558
angiography, Aug., 555–557
computed tomography, Aug., 558
cystography, Aug., 551, 554–555
Doppler examination of testes, Aug., 557–558
excretory urography, Aug., 549–550

Urologic procedures (*Continued*)
for bladder outlet obstruction, excretory urography, nuclear imaging of testes, Aug., 558
plain abdominal film, Aug., 549
ultrasonography, Aug., 555
urethrography, Aug., 551
urine analysis, Aug., 548
therapeutic procedures, Aug., 543–547
catheterization, Aug., 543–547
manual spermatic cord detorsion, Aug., 547

V-Q inequality, hypoxemia due to, Aug., 428–429
Vaginitis, microbiologic studies of, May, 358
Vascular access, in trauma victim, Nov., 698–699
Veins, femoral, catheters inserted via, Nov., 723
Venipuncture, infraclavicular subclavian, Nov., 717–718
internal jugular-subclavian junctional, Nov., 716–717
supraclavicular subclavian, Nov., 713–716
Venous access, central. See *Central venous access.*
for transvenous cardiac pacing, Nov., 747
Venous cut-down, in critically ill patient, Nov., 727–728
in trauma victim, Nov., 698–699
Ventilators, classification of, Nov., 638–640
pressure preset, Nov., 639
volume preset, Nov., 639–640
Ventilatory management, arterial blood gases in, May, 237, 245–247
of critically ill patient, Nov., **635–654.**
See also *Airways; Mechanical ventilation.*
acute vs. chronic respiratory failure, Nov., 635–636
adjuncts to mechanical ventilation, Nov., 644–647
classification of ventilators, Nov., 638–640
complete vs. partial ventilatory support, Nov., 647–648
discontinuing mechanical ventilatory support, Nov., 651–653
indications for intubation, Nov., 636
indications for mechanical ventilation, Nov., 636–638
initiating mechanical ventilatory support, Nov., 648–650
modes of ventilation, Nov., 642–644
physiologic implications of PPV, Nov., 640–641
Ventricular fibrillation, for ventricular tachycardia, Nov., 770
Verapamil, for wide-complex PSVT, Nov., 769
Viral hepatitis, indications for, May, 308
prophylaxis for, May, 308–311
serologic markers in, May, 306–308
Type A, May, 306
Type B, May, 306–308
serologic tests in, May, 305–311
Vital signs, in invasive cardiorespiratory monitoring, Nov., 776–777
Volvulus, sigmoid, endoscopy for, Aug., 506
von Willebrand's disease, determination of, Feb., 100–101

White blood cell count, and differential, Feb., **41–58**
clinical applications of, Feb., 51–54
for cerebral spinal fluid, May, 286–287
test selection for, Feb., 54–55
in diagnosis of bacteremia, Feb., 4–5
White blood cells, measurement of, errors in, Feb., 47–48
interpretation of, Feb., 45–48
methods of, Feb., 43–45
patient population and, Feb., 45, 47
normal values for, Feb., 46, 47
physiology and pathophysiology of, Feb., 41–42
Wounds, of skin, microbiologic studies of, May, 359
puncture. See *Puncture wounds.*

Zeta sedimentation rate (ZSR), determination of, Feb., **87–93**; May, 387
interpretation of, Feb., 90–92